Citius Oncology, Inc. (NasdaqCM: CTOR)
Health Care · Biotechnology · US
$0.81
-3.24% today · -51.5% 1Y
Citius Oncology, Inc. (NasdaqCM: CTOR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $88.82M and employs 285 people.
Over the last twelve months the share price has lost 51.5%, trading between 0.49 and 2.25.
Tweenvest scores Citius Oncology, Inc. across four factors: quality 51/100, value 54/100. Its strongest factor is value.
CTOR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $88.82M
- Revenue (TTM)
- $7.11M
- P/E
- —
- EPS
- -0.49
- Dividend yield
- —
- Beta (5Y)
- 3.40
- 52-week high
- $2.25
- 52-week low
- $0.49
- Avg volume (3M)
- —
- Shares outstanding
- 105.76M
- Employees
- 285
- Next earnings
- —
About Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
- ISIN
- US17331Y1091
- Listed since
- Dec 8, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Rallybio CorporationNasdaqCM: RLYB | $90.38M | $16.75 | -1.59% |
| Equillium, Inc.NasdaqCM: EQ | $89.41M | $1.49 | +5.67% |
| ViGenCell Inc.KOSDAQ: A308080 | $89.05M | ₩5,840.00 | +0.52% |
| ImmuCell CorporationNasdaqCM: ICCC | $89.01M | $10.60 | +8.16% |
| Bonraybio Co., Ltd.TWSE: 6955 | $88.36M | NT$93.00 | -0.53% |
| Y-Biologics, Inc.KOSDAQ: A338840 | $87.21M | ₩7,630.00 | -10.45% |
| Revium Rx.OTCPK: RVRC | $86.84M | $— | — |
| Quantum Cyber N.V.NasdaqCM: QUCY | $86.59M | $1.02 | -0.97% |
Figures last refreshed Oct 11, 2026.